TREATMENT PATTERNS OF BIOLOGICS AND APREMILAST AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS BY PSORIATIC ARTHRITIS STATUS

被引：0
|
作者：
Feldman, S. R. [1 ]
Zhang, J. [2 ]
Martinez, D. [3 ]
Lopez-Gonzalez, L. [4 ]
Marchlewicz, E. [5 ]
Shrady, G. [4 ]
Lowry, S. [2 ]
Mendelsohn, A. B. [2 ]
Zhao, Y. [2 ]
机构：
[1] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA
[2] Sun Pharmaceut Ind Inc, Princeton, NJ USA
[3] IBM Watson Hlth, Bethesda, MD USA
[4] IBM Watson Hlth, Cambridge, MA USA
[5] IBM Watson Hlth, Ann Arbor, MI USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.123
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PBI41
引用
收藏
页码：S55 / S55
页数：1
相关论文
共 50 条
  • [1] Long-Term Treatment Patterns of Biologics and Apremilast Among Patients with Moderate-to-Severe Plaque Psoriasis by Psoriatic Arthritis Status
    Feldman, Steven
    Zhang, Jingchuan
    Martinez, Diane
    Lopez-Gonzalez, Lorena
    Marchlewicz, Elizabeth Holt
    Shrady, George
    Mendelsohn, Alan
    Zhao, Yang
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [2] TREATMENT PATTERNS OF BIOLOGICS AND APREMILAST AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS BY METABOLIC SYNDROME STATUS
    Feldman, S. R.
    Zhang, J.
    Martinez, D.
    Lopez-Gonzalez, L.
    Marchlewicz, E.
    Shrady, G.
    Lowry, S.
    Mendelsohn, A. B.
    Zhao, Y.
    [J]. VALUE IN HEALTH, 2019, 22 : S54 - S54
  • [3] Improvements in scalp and nail psoriasis with apremilast treatment in patients with moderate to severe plaque psoriasis with and without a history of psoriatic arthritis
    Crowley, Jeffrey
    Gooderham, Melinda
    Richter, Sven
    Shi, Rebecca
    Reich, Kristian
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB62 - AB62
  • [4] Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status
    Feldman, Steven R.
    Zhang, Jingchuan
    Martinez, Diane J.
    Lopez-Gonzalez, Lorena
    Marchlewicz, Elizabeth Hoit
    Shrady, George
    Mendelsohn, Alan M.
    Zhao, Yang
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2021, 32 (02) : 203 - 211
  • [5] Psoriasis and psoriatic arthritis: risk of infection with biologics and apremilast
    Lorenz, Judith
    [J]. AKTUELLE DERMATOLOGIE, 2023, 49 (06)
  • [6] Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis
    Feldman, Steven R.
    Pelletier, Corey L.
    Wilson, Kathleen L.
    Mehta, Rina K.
    Brouillette, Matthew A.
    Smith, David
    Bonafede, Machaon M.
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (09) : 699 - 708
  • [7] Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis
    Vu, Trang T.
    Gooderham, Melinda
    Papp, Kim
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (11) : 1423 - 1433
  • [8] Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence
    Sebastian Hinde
    Ros Wade
    Stephen Palmer
    Nerys Woolacott
    Eldon Spackman
    [J]. PharmacoEconomics, 2016, 34 : 587 - 596
  • [9] Oral apremilast is active in the treatment of moderate to severe plaque psoriasis
    Papp, Kim
    Hu, Angela
    Day, Robert
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB147 - AB147
  • [10] Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence
    Hinde, Sebastian
    Wade, Ros
    Palmer, Stephen
    Woolacott, Nerys
    Spackman, Eldon
    [J]. PHARMACOECONOMICS, 2016, 34 (06) : 587 - 596
12345